Abstract The efficacy of telithromycin has been assessed in six Phase III studies involving adults with mild to moderate community-acquired pneumonia (CAP) with a degree of severity compatible with oral therapy. Patients received telithromycin 800 mg once daily for 7^10 days in three open-label studies (n=870) and three randomized, double-blind, comparator-controlled studies (n=503). Comparator antibacterials were amoxicillin 1000 mg three-times daily, clarithromycin 500 mg twice daily and trovafloxacin 200 mg once daily. Clinical and bacteriological outcomes were assessed 7^14 days post-therapy. Among telithromycin-treated patients, per-protocol clinical cure rates were 93.1and 91.0% for the open-label and comparative studies, respectively.Telithromycin treatment was as effective as the comparator agents. High eradication and clinical cure rates were observed for infections caused by key pathogens: Streptococcus pneumoniae including isolates resistant to penicillin G and/or erythromycin A (95.4%), Haemophilus influenzae (89.5%) and Moraxella catarrhalis (90%). Telithromycin was also highly effective in patients with infections caused by atypical and/or intracellular pathogens and those at increased risk of morbidity.Telithromycin was generally well tolerated. Telithromycin 800 mg once daily for 7^10 days offers a convenient and well-tolerated first-line oral therapy for the empirical treatment of mild to moderate CAP. r
INTRODUCTION
Community-acquired pneumonia (CAP) is a signi¢cant cause of morbidity and mortality worldwide. In the USA, there are up to 3 million cases of CAP each year, accounting for approximately 10 million physician visits, 500 000 hospitalizations, and 45 000 deaths (1, 2) . Similarly, in Germany, severe CAP accounts for approximately 10% of hospitalized patients (3) , and in the United Kingdom, mortality rates among hospitalized patients range from 6^12% (4) .
The majority of CAP cases are caused by bacterial infections, with Streptococcus pneumoniae, Haemophilus in£uenzae and Moraxella catarrhalis being the three most frequent typical bacterial pathogens isolated. The number of cases caused by M. catarrhalis infections is much lower than that caused by S. pneumoniae or H. in£uenzae. S. pneumoniae is the most frequently isolated pathogen and is responsible for 20^40% of all cases of CAP where a speci¢c pathogen is identi¢ed (4, 5) . Additionally, atypical and/or intracellular pathogens, such as Mycoplasma pneumoniae, Chlamydophila (Chlamydia) pneumoniae and Legionella pneumophila, have been reported to account for a signi¢cant number of cases of CAP (6) , and may often be present in addition to a typical pathogen (4) . CAP caused by L. pneumophila is often associated with more severe infection and is linked with a high risk of mortality (15%) (7^9).
Despite the development of better diagnostic techniques, up to 50% of all reported cases of CAP will have no pathogen identi¢ed and initial treatment is of necessity largely empirical (2, 7, 10) . There is an increasing trend for outpatient therapy for patients that would previously have been hospitalized.This has been encouraged by the development of the Fine criteria to identify patients at low risk of death and is supported by the results of several studies that demonstrate that many patients with CAP can be adequately treated on an ambulatory basis (11^13). Current treatment options for CAP include blactams, macrolides, £uoroquinolones and doxycycline.
In recent years, the choices for empirical therapy have become limited by the emergence and spread of pathogens that are resistant to many of the currently used ¢rst-line antibacterials, a problem that is steadily increasing worldwide. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT) is an international surveillance study which documents the antibacterial susceptibility of pathogens isolated from patients with community-acquired respiratory tract infections (RTIs). Preliminary results for S. pneumoniae isolates worldwide con¢rm the increasing problem of resistance to many antibacterial agents including penicillin (minimum inhibitory concentration [MIC] Z 2.0 mg l
À1
; 42.3%) and erythromycin A (MIC Z1.0 mg l À1 ; 42.7%) (14) . However, there is regional variation in the incidence of resistance. In Europe, for example, penicillin resistance rates are o10% in a number of countries, including Sweden, Germany, The Netherlands and the UK (15, 16) . ErythromycinA resistance is of particular concern as it can confer cross-resistance to all macrolides, lincosamides and streptogramin group B (MLS B ) antibacterials. Many penicillin-resistant pneumococci are also becoming increasingly resistant to the newer macrolides and £uoroquinolones (17^20). The development of resistance is closely linked with regional prescription and usage patterns for macrolides, penicillins and £uoroquinolones. (17,21^23) . In the case of macrolides, resistance in the USA was reported to double in the 5 years between 1995 and 1999 and is now generally 420% (23) .
Failure to eradicate bacterial infections because of increased resistance may result in poor clinical outcomes (24^27). This highlights the need for new antibacterial treatments that are highly e¡ective against resistant pathogens and that have a low propensity to select for or induce resistance or cross-resistance, yet can still be used empirically.
Telithromycin is the ¢rst compound in a new class of antibacterialsFthe ketolidesFto be approved for clinical use. Ketolides are a novel addition to the MLS B family of antibacterials, but have several important structural and functional di¡erences. In telithromycin, the C3 cladinose sugar of macrolides, previously thought to be essential for antibacterial activity, has been substituted with a keto group (Fig. 1) . The keto group confers excellent acid stability (28) , and has also been shown to prevent induction of MLS B resistance by ketolides in vitro (29, 30) . Furthermore, the addition of a C11,12-carbamate side chain enhances both antibacterial activity and binding to MLS B -resistant ribosomes, which may explain telithromycin's ability to overcome MLS B resistance (31^33).
Telithromycin acts at two levels: by inhibiting the assembly of ribosomes (as do macrolides) and by inhibiting translation through interactions with domains II and V of the 23S rRNA. In contrast to macrolides, telithromycin interacts strongly with nucleotide A752 in domain II and this appears to account for its ability to bind to MLS B -resistant ribosomes (31^35). Thus, telithromycin has been speci¢cally designed to preserve antibacterial activity while circumventing selection of resistance and hence to provide optimal therapy for CAP and other upper and lower community-acquired RTIs (36) .
Telithromycin provides a well-balanced spectrum of activity against the key respiratory pathogens (Table 1 ) (37^42). In vitro, telithromycin is 2-to 4 -fold more potent than clarithromycin or azithromycin against susceptible S. pneumoniae, and at least 10 -fold more potent than these agents against S. pneumoniae isolates with intermediate or full resistance to b-lactams or erythromycin A (37). Telithromycin's activity against erythromycin Aresistant pneumococci not only includes mef-positive (ef£ux) isolates, but also extends to isolates showing inducible and constitutive MLS B (erm) resistance (43) . In addition, many isolates that have been shown to be resistant to macrolides through mutations of the drug^ribo-some binding site remain susceptible to telithromycin (44) . Against H. in£uenzae, telithromycin demonstrates a level of activity comparable with that of the newer macrolides azithromycin and clarithromycin (38) . Telithromycin is highly active against atypical respiratory pathogens such as M. pneumoniae, and the intracellular pathogens C. pneumoniae and L. pneumophila (394 1, 45, 46) . Additionally, telithromycin possesses a low potential to select for resistance or induce cross-resistance to other MLS B antibacterials (47, 48) .
Telithromycin exhibits ideal coverage for bacterial pathogens causing community-acquired RTIs. This spectrum of activity encompasses common and atypical/ intracellular pathogens including resistant strains, making it an attractive new option for empirical treatment of mild to moderate CAP and other community-acquired upper and lower RTIs.
Telithromycin is administered orally at a recommended once-daily dosage of 800 mg (2 Â 400 mg tablets). At this dosage, it rapidly reaches maximal plasma concentrations and penetrates into bronchopulmonary tissues and £uids. Pharmacokinetic/pharmacodynamic studies in animals and humans have demonstrated that the e⁄cacy of telithromycin in vivo is concentration dependent and correlates with its area under the concentration^time curve AUC/MIC ratio (49, 50) . Concentrations at the site of infection are maintained above the MIC for most respiratory pathogens for up to 24 h after dosing (51, 52) . In contrast to azithromycin, telithromycin also maintains e¡ective concentrations in plasma throughout the dosing period (53, 54) . This paper reviews the clinical and bacteriological e⁄-cacy of telithromycin in the treatment of 1373 patients with mild to moderate CAP in six Phase III, multicentre, multinational clinical trials (conducted between February 1998 and September 2000): three double-blind, randomized, controlled comparative studies (n=573) and three open-label studies (n=870); Table 2 ) (55^60).
METHODS
Enrolment criteria for patients in all six trials included a radiologically con¢rmed diagnosis of CAP and the presence of at least two signs and symptoms of CAP (cough, production of purulent sputum, auscultatory ¢ndings, dyspnoea, fever, white blood cell count 410 000 mm
À3
or Gram-positive diplococci in sputum). Both in-and outpatients were included in the studies but those for whom oral medication was not appropriate were excluded, as were patients who had received treatment with other antibacterials in the last 7 days.
Patients received two 400 mg telithromycin tablets (total 800 mg) orally once daily for 7^10 days or a comparator agent ( Table 2 ).The comparator drugs chosen included high-dose amoxicillin and clarithromycin, both recommended as ¢rst-line treatments in international guidelines (4, 61, 62) , and trova£oxacin. At the time of the studies, trova£oxacin was selected because it was one of the most potent £uoroquinolones available. Patients were assessed on separate visits: pretherapy/entry (day 1), on-therapy (days 3^5), end of therapy (days 11^13), post-therapy/test of cure (TOC) (days 17^24) and late post-therapy (days 31^45). The post-therapy/TOC visit was designed to capture early relapses as failures and thus provide a vigorous test of e⁄cacy.
Patients with a con¢rmed diagnosis of CAP receiving at least one dose of study medication were included in the modi¢ed intent-to-treat (mITT) population. Patients with no major protocol deviations following randomization were included in the per-protocol analysis. Clinical and bacteriological outcomes were determined at the post-therapy/TOC visit.
The clinical outcome assessment was based on clinical signs, symptoms and X-ray ¢ndings and was classi¢ed as cure, failure or intermediate. Cure was further distinguished as either returning to the preinfection state or with improved symptoms. Subjects with residual symptoms requiring further antibacterial treatment were classi¢ed as failure.
Pathogens isolated from pretherapy blood and sputum samples were considered causative for CAP. Isolates were tested for their susceptibility to penicillin G, erythromycin A and telithromycin by National Committee for Clinical Laboratory Standards (NCCLS) MIC testing at two central laboratories. Infections due to atypical pathogens were diagnosed by serology and/or polymerase chain reaction (PCR) analysis of sputum samples following stringent criteria (based on US Food and Drug Administration recommendations). Patients were considered to have an atypical infection if they had a negative culture for typical pathogens and met the following criteria: C. pneumoniaeFpositive culture, 4 -fold increase in Satisfactory bacteriological outcome was de¢ned as documented eradication of the causative pathogen or clinical improvement to the extent that a follow-up *Number of patients with a con¢rmed diagnosis who received atleastone dose of study medication (modi¢edintent-to-treat population). bid: twice daily; qd: once daily; tid: three-times daily. culture could not be obtained and the pathogen was, therefore, presumed to be eradicated. Conversely, presumed bacterial failure occurred when, by de¢nition, clinical failure was the outcome. While this criterion may overstate true microbiological failure, it was applied consistently to all study arms. Safety assessments were carried out on all patients who had received at least one dose of study medication, and who had at least one post-baseline clinical or laboratory assessment. All adverse events, whether reported spontaneously by the patients or observed by the investigator, were recorded. In addition, laboratory ¢ndings or results of other diagnostic procedures (including 12-lead electrocardiograms [ECG]) considered to be clinically relevant were reported as adverse events.
RESULTS AND DISCUSSION

Clinical and bacteriological e⁄cacy
Per-protocol analysis of clinical cure rates demonstrated that a 7-to 10 -day course of telithromycin 800 mg (once daily) was at least as e¡ective as standard antibacterials (Table 3) : amoxicillin 1000 mg three-times daily for 10 days; clarithromycin 500 mg twice daily for 10 days; trova£oxacin 200 mg once daily for 7^10 days (55^57). Telithromycin achieved a high overall clinical cure rate in the comparator studies of 91.0%.
Clinical cure rates for telithromycin were similar in the open-label studies (Table 3 ) (58^60).The overall clinical cure rate in the open-label studies was 93.1%.
The results for clinical outcome in the mITT population con¢rmed the per-protocol analysis, demonstrating equivalence to comparator agents ( Table 3) . The clinical cure rates in this population supported the good clinical e⁄cacy demonstrated in the per-protocol population, but were slightly lower due to the inclusion of patients with indeterminate outcomes.
Consistent with the high clinical cure rate, 90.2 and 90.8% of telithromycin-treated patients achieved a satisfactory bacteriological outcome in the controlled and open-label studies, respectively. As expected, S. pneumoniae and H. in£uenzae were the most commonly isolated pathogens (Fig. 2) . The MICs of telithromycin for key causative pathogens isolated in these studies are detailed in Table 4 . All isolates of S. pneumoniae were susceptible to telithromycin at a tentative susceptibility breakpoint of r 1.0 mg l À1 (mode 0.016 mg l
À1
), and all H. in£uenzae isolates, irrespective of b-lactamase production, were inhibited by r 8 mgl À1 telithromycin (mode 2 mg l
). The pooled analysis of bacteriological eradication and clinical cure rates by pathogen in telithromycin-treated patients is summarized in Table 5 . Per-protocol populations with causative agents identi¢ed at pretreatment showed high eradication rates for common pathogens.
High clinical cure and eradication rates were observed for patients with infections caused by S. pneumoniae (94.8% clinical cure, 95.4% eradication). Patients infected with penicillin G-and/or macrolide (erythromycin A)-resistant S. pneumoniae had comparable rates of clinical cure and bacterial eradication ( Table 6 ). The macrolide (erythromycin A)-resistant isolates included both mef and erm isolates (MIC range 4 to 4512 mg l
). The rates of clinical cure and bacterial eradication were also high for the Gram-negative pathogens H. in£u-enzae (89.5% clinical cure, 90.5% eradication) and M. catarrhalis (90.0% clinical cure, 86.7% eradication). All of the 5 patients with infections caused by H. in£uenzae strains with telithromycin MICs of 8 mg l À1 achieved clinical cure with corresponding bacterial eradication. Fourteen patients with H. in£uenzae infections were infected with b-lactamase producing strains of this pathogen.Of these 14 patients, 12 (85.7%) achieved both bacterial eradication and clinical cure at the post-therapy/TOCvisit, comparable with the overall eradication and clinical cure rates for H. in£uenzae infected patients.
Clinical cure and bacterial eradication rates in patients with staphylococcal pneumonia were also good (78.9% clinical cure, 78.9% eradication) given that pneumonia caused by S. aureus is often severe, frequently associated with viral infection and di⁄cult to treat (63) .
Telithromycin showed excellent clinical e⁄cacy against infections caused by the atypical and/or intracellular pathogens C. pneumoniae, M. pneumoniae and L. pneumophila, with cure rates of 94.1, 96.8 and 100%, respectively (Fig. 3) .
Certain patients with CAP are at increased risk of morbidity and mortality, i.e. the elderly (Z 65 years of age) and those with more severe disease (e.g. Fine score class ZIII [10] ) or with pneumococcal bacteraemia. Once-daily oral therapy with telithromycin was highly effective in these at-risk patient groups (Fig. 4) .Clinical outcomes for these patient groups were similar to that of the overall population.For those patients with bacteraemia who were reported as clinical failures, only one was a documented bacteriological failure. Of those patients in the per-protocol population, 20% were hospitalized on admission to the study. Clinical cure rates for nonhospitalized and hospitalized patients were 92.6 and 92.4%, respectively. Telithromycin may therefore be an e¡ective treatment for those CAP patients admitted to hospital for whom oral therapy is appropriate.
Tolerability and safety of telithromycin in the treatment of patients with CAP
The tolerability and safety of telithromycin have been established in three comparative Phase III clinical trials in CAP patients.
Telithromycin treatment was generally well tolerated and was associated with a low rate of treatment discontinuation (4.9%). Most adverse events were of mild to moderate intensity.The most frequent treatment-related events were diarrhoea (13.1%), nausea (8.0%), vomiting (2.3%) and dizziness (2.1%). Although telithromycin treatment was associated with a higher incidence of diarrhoea vs. individual comparatorsF5.9% (amoxicillin), 6.4 % (trova£oxacin), 7.2% (clarithromycin)Fmost instances were mild and no telithromycin-treated patients in the comparative studies discontinued treatment as a result of diarrhoea.
There was no evidence that telithromycin is associated with an excess risk of hepatic e¡ects. The e¡ects of telithromycin on liver function tests and the adverseevents pro¢le were similar to that of the macrolide group.
There was no signi¢cant di¡erence in ECG e¡ects or in the incidence of cardiovascular adverse events when telithromycin was compared with both macrolide and nonmacrolide antibacterials. Telithromycin was comparable to clarithromycin with respect to QTc changes.
The safety pro¢le of telithromycin in the open-label studies was similar to that in the comparative studies described above. In one of the open-label studies (58), the incidence of elevated alanine transaminase (ALT) levels (11.3%) was higher than that observed in any of the other CAP studies.The majority of the a¡ected patients in this study had ALT levels above the normal range at the pretherapy visit.Thus, the higher incidence of clinically noteworthy abnormal laboratory values for ALT levels observed in this study may be accounted for by di¡er-ences in the disease characteristics of this study population. These patients had higher baseline morbidity, demonstrated by the 74% of patients hospitalized on entry to this study compared with 0^35.7% of patients in other studies.
CONCLUSIONS
At a convenient dosage of 800 mg once daily for 7^10 days in the treatment of mild to moderate CAP, telithromycin was well tolerated and achieved high rates of clinical cure and satisfactory bacteriological outcome vs. a broad range of comparative agents. This favourable pro¢le extends to patients with mild to moderate CAP due to both typical and atypical/intracellular pathogens and even to those patients with infection due to penicillinand/or macrolide-resistant S. pneumoniae, and b-lactamase producing strains of H. in£uenzae.
Telithromycin provides excellent e⁄cacy in subgroups of vulnerable patients who are at increased risk of morbidity and mortality, such as the elderly and those with more severe infection (Fine score class Z III or those with pneumococcal bacteraemia). Interestingly, there is a growing awareness that treatment with oral antibacterials is often appropriate for hospitalized patients with non-severe CAP (4) .
On the basis of these ¢ndings, telithromycin represents a promising new oral antibacterial agent for ¢rst-line empirical therapy of mild to moderate CAP in all patient groups. 
